Induced pluripotent stem (iPS) cells have the potential to revolutionise medicine
Induced pluripotent stem (iPS) cells have the potential to revolutionise medicine, however if we want to use them in clinical settings we need to find better ways to make them, so that they are safer and of the highest quality possible. In this work we have identified a new cell type, the endothelial progenitor cell (EPC), that can be isolated from blood. This allows us a very practical and efficient way of making iPS cells from the widest possible number of patients. These iPS cells also have unaltered karyotypes compared to the EPCs used to generate them, which is important if we want to develop use iPS cells in cell therapies in the future. We are currently using these iPS cells to model diseases and in tailored drug screening.